Rushad Patell

Rushad Patell

Auto-generated profile, based on publicly available information

Rushad Patell

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
RPRushad Patell
Rushad Patell
TBThomas Bogue
Thomas Bogue
AKAnita Koshy
Anita Koshy
PBPoorva Bindal
Poorva Bindal
MMMwanasha Merrill
Mwanasha Merrill
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 days). The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care. The cumulative incidence of thrombosis (including arterial and venous events) at day 30 following discharge was 2.5% (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was 0.6% (95% CI, 0.1-4.6). The 30-day cumulative incidence of major hemorrhage was 0.7% (95% CI, 0.1-5.1) and of clinically relevant nonmajor bleeds was 2.9% (95% CI, 1.0-9.1). We conclude that the rates of thrombosis and hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need for randomized data to inform recommendations for universal postdischarge thromboprophylaxis.

27 February 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
RPRushad Patell
Rushad Patell
LRLisa Rybicki
Lisa Rybicki
KMKeith R. McCrae
Keith R. McCrae
AKAlok A. Khorana
Alok A. Khorana
Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer varies and prophylaxis is inconsistently used. A previously validated tool (Khorana Score, [KS]) identifies VTE risk in cancer outpatients with 5 easily available variables but has not been studied in the inpatient setting. We evaluated the validity of KS in predicting VTE risk in hospitalized cancer patients. We conducted a retrospective cohort study of consecutive oncology inpatients at the Cleveland Clinic from 11/2012 to 12/2014 (n = 3531). Patients were excluded for VTE on admission (n = 304), incomplete KS data (n = 439) or other reasons (n = 8). Data collected included demographics, cancer type, length of stay (LOS), anticoagulant use, and laboratory values. Multivariate risk factors were identified with stepwise logistic regression, confirmed with bootstrap analysis. Of 2780 patients included, 106 (3.8%) developed VTE during hospitalization. Median age was 62 (range, 19‐98) years and 56% were male. Median LOS was 5 (range, 0‐152) days. High risk KS (≥ 3) was significantly associated with VTE in uni‐ and multivariate analyses (OR 2.5, 95% [confidence interval] CI 1.3‐4.9). Other significant variables included male gender (OR 1.67, 1.1‐2.53), older age (OR 0.86, 0.75‐0.99) and use of anticoagulants (OR 0.57, 0.39‐0.85). Recursive partitioning analysis suggested optimal cut point for KS is 2 (OR 1.82, 1.23‐2.69). This is the first report validating KS as a risk tool to predict VTE in hospitalized cancer patients. Using this tool could lead to more consistent and successful application of inpatient thromboprophylaxis.

21 July 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
RPRushad Patell
Rushad Patell
TBThomas Bogue
Thomas Bogue
PBPoorva Bindal
Poorva Bindal
AKAnita Koshy
Anita Koshy
MMMwanasha Merrill
Mwanasha Merrill
JZJeffrey I. Zwicker
Jeffrey I. Zwicker

4 October 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
TCThita Chiasakul
Thita Chiasakul
BLBarbara D. Lam
Barbara D. Lam
MMMegan McNichol
Megan McNichol
WRWilliam Robertson
William Robertson
RRRachel P. Rosovsky
Rachel P. Rosovsky
RPRushad Patell
Rushad Patell

13 July 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
RPRushad Patell
Rushad Patell
AKAdeel M Khan
Adeel M Khan
TBThomas Bogue
Thomas Bogue
MMMwanasha Merrill
Mwanasha Merrill
AKAnita Koshy
Anita Koshy
JZJeffrey I Zwicker
Jeffrey I Zwicker
Click on the article title to read more.

23 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CHCharles Hsu
Charles Hsu
RPRushad Patell
Rushad Patell
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
Venous thromboembolism (VTE) and thrombocytopenia are frequently encountered complications in patients with cancer. Although there are several studies evaluating the safety and efficacy of anticoagulation regimens in patients with cancer-associated thrombosis (CAT) with thrombocytopenia, there is a paucity of data assessing the scope of the concurrent diagnoses. This study evaluates the prevalence of thrombocytopenia among patients with acute CAT. A retrospective cohort analysis of adult patients with cancer was conducted at Beth Israel Deaconess Medical Center between 2010 and 2021 with CAT (acute VTE within 6 months after new diagnosis of malignancy). VTE included acute deep vein thrombosis, pulmonary embolism, abdominal or intrathoracic venous thrombosis, and cerebral sinus thrombosis. The lowest platelet count within 2 weeks of (before or after) the index VTE event was identified to assess the frequency and grade of concurrent thrombocytopenia. We identified 3635 patients with CAT (80% solid tumors, 18% hematologic malignancies, and 2% multiple concurrent cancer diagnoses). Thrombocytopenia (defined as platelet count <100 000/μL) occurred in 22% (95% CI 21%-24%) of patients with CAT with solid tumors diagnoses and 47% (95% CI 43%-51%) of patients with CAT and hematologic malignancies. Severe thrombocytopenia (platelet count <50 000/μL) occurred in 7% (95% CI 6%-8%) of patients with solid tumors and 30% (95% CI 27%-34%) of patients with hematologic malignancies. Concurrent diagnoses of CAT and thrombocytopenia are very common, especially among patients with hematologic malignancies.